Gram-Negative Infections | Unmet Need | HABP/VABP Gram-Negative Infections | US/EU | 2019

MARKET OUTLOOK

Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are among the most common and serious infections in the hospital setting. HABP/VABP due to carbapenem-resistant organisms (CROs) are particularly difficult-to-treat and life-threatening. No current antibiotic was specifically developed for CROs. Allergan/Pfizer’s Avycaz/Zavicefta and Melinta’s Vabomere address some of the unmet need in this area, but most current treatments are combinations of generically available antibiotics and have significant side effects and/or suboptimal efficacy.

QUESTIONS ANSWERED

• What clinical and nonclinical factors are the key influences on ID specialists’ prescribing decisions for HABP/VABP due to CROs? How do these different factors compare in terms of importance?
• How do current therapies for HABP/VABP due to CROs—including Avycaz/Zavicefta and Vabomere—perform on clinical and nonclinical attributes?
• What are the key areas of unmet need that represent opportunities for developers of therapies for the treatment of HABP/VABP due to CROs?
• What trade-offs across clinical and nonclinical attributes and price are acceptable to U.S. and European ID specialists for a hypothetical new agent for the treatment of HABP/VABP due to CROs?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 30 European ID specialists fielded in February 2019

Key drugs: Avycaz/Zavicefta, Vabomere, tigecycline, meropenem, imipenem/cilastatin, colistin

Key metrics included: 

• Target Product Profile (TPP) simulator based on conjoint analysis methodology.
• Stated vs. derived importance of product attributes on prescribing behavior.
• Assessment of current drug performance against treatment drivers and goals.
• Physician perceptions of unmet needs in the indication and related indications.
• Analysis of remaining drug development opportunities.